title: Antidotes edge closer to reversing effects of new blood thinners.
authors: Elie
authors: E
authors: Dolgin
mesh_terms: D000818:Animals; D000925:Anticoagulants / Q000037:antagonists & inhibitors* / Q000627:therapeutic use; D001562:Benzimidazoles / Q000037:antagonists & inhibitors / Q000627:therapeutic use; D000069604:Dabigatran; D015951:Factor Xa / Q000378:metabolism / Q000494:pharmacology*; D006801:Humans; D011720:Pyrazoles / Q000037:antagonists & inhibitors / Q000627:therapeutic use; D011728:Pyridones / Q000037:antagonists & inhibitors / Q000627:therapeutic use; D011994:Recombinant Proteins / Q000378:metabolism / Q000494:pharmacology*; D014812:Vitamin K / Q000494:pharmacology / Q000627:therapeutic use; D014859:Warfarin / Q000037:antagonists & inhibitors / Q000627:therapeutic use; D015091:beta-Alanine / Q000031:analogs & derivatives / Q000037:antagonists & inhibitors / Q000627:therapeutic use
chemical_list: D000925:Anticoagulants; D001562:Benzimidazoles; C580915:PRT064445; D011720:Pyrazoles; D011728:Pyridones; D011994:Recombinant Proteins; D015091:beta-Alanine; D014812:Vitamin K; C522181:apixaban; D014859:Warfarin; D015951:Factor Xa; D000069604:Dabigatran